Sourav Bandyopadhyay, PhD

Title(s)Professor, Bioengineering
SchoolSchool of Pharmacy
Address1450 Third Street, #001
San Francisco CA 94158
Phone415-476-3425
PronounsHe/Him/His
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Sourav Bandyopadhyay obtained his PhD in Bioinformatics and Systems Biology with Trey Ideker (UC San Diego) where he made seminal contributions to our understanding of the organization and plasticity of physical and genetic interaction networks, (Bandyopadhyay et al. Science 2010, Nature Methods 2010, PLoS Computational Biology 2008). In 2010 he began an independent research career through the prestigious UCSF faculty fellowship designed to provide early independence to the world’s best scientists.

    The Bandyopadhyay lab employs new cellular and molecular technologies to tackle the most urgent and clinically important problems in cancer therapy, including functional genomics, drug screens, proteomics and single cell approaches. Critically, these technologies often generate the scale and complexity of data that necessitate the development of new computational algorithms to maximize their impact and fully understand their relevance in the clinic. The lab is focused on identifying mechanisms of drug resistance and targetable synthetic lethal interactions in breast and lung cancers since these diseases are deadly in the metastatic setting and demonstrate suboptimal tumor responses even with out best, most targeted therapies. We are committed to the identification, mechanistic dissection and clinical translation of new targets and target combinations through broad collaborations with biotechnologists, chemists, clinicians and pharma.

    Collapse Research 
    Collapse Research Activities and Funding
    Stress responses drive resistance and shape tumor evolution in EGFR mutant lung cancer
    NIH R01CA238236Feb 20, 2020 - Jan 31, 2025
    Role: Principal Investigator
    The Cancer Target Discovery and Development Network at UCSF
    NIH U01CA217882Aug 10, 2017 - Jul 31, 2022
    Role: Co-Principal Investigator
    Physical and Genetic Interaction Landscape of the Tyrosine Kinome
    NIH R01GM107671Sep 1, 2014 - Jun 30, 2019
    Role: Principal Investigator
    Multiscale analysis of influenza host-pathogen interactions: Fluomics
    NIH U19AI106754Jun 26, 2013 - May 31, 2018
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Academic Senate

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat Commun. 2024 May 03; 15(1):3741. Haderk F, Chou YT, Cech L, Fernández-Méndez C, Yu J, Olivas V, Meraz IM, Barbosa Rabago D, Kerr DL, Gomez C, Allegakoen DV, Guan J, Shah KN, Herrington KA, Gbenedio OM, Nanjo S, Majidi M, Tamaki W, Pourmoghadam YK, Rotow JK, McCoach CE, Riess JW, Gutkind JS, Tang TT, Post L, Huang B, Santisteban P, Goodarzi H, Bandyopadhyay S, Kuo CJ, Roose JP, Wu W, Blakely CM, Roth JA, Bivona TG. PMID: 38702301; PMCID: PMC11068778.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    2. Abstract 4653: Unraveling the vulnerabilities of targeted therapy-tolerant persister cells in NSCLC. Cancer Research. 2024 Mar 22; 84(6_Supplement):4653-4653. Kim KD, Kuchenov KD, Zaman ZA, Bennett BN, Ramos RE, Nakamura NK, Wiita WA, Bandyopadhyay BS, Bivona BT. .
      View in: Publisher Site   Mentions:
    3. An inflamed tumor cell subpopulation promotes chemotherapy resistance in triple negative breast cancer. Sci Rep. 2024 02 14; 14(1):3694. Jacobo Jacobo M, Donnella HJ, Sobti S, Kaushik S, Goga A, Bandyopadhyay S. PMID: 38355954; PMCID: PMC10866903.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    4. Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes. Front Oncol. 2023; 13:1192208. Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M. PMID: 37384294; PMCID: PMC10294228.
      View in: PubMed   Mentions:
    5. A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer. Oncogene. 2023 Jul; 42(28):2207-2217. Meng D, Zhao X, Yang YC, Navickas A, Helland C, Goodarzi H, Singh M, Bandyopadhyay S. PMID: 37264081; PMCID: PMC10328828.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    6. Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Res. 2022 Sep 02; 82(17):3187. Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR. PMID: 36052496.
      View in: PubMed   Mentions: 1     Fields:    
    7. Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Res. 2022 Sep 02; 82(17):3188. Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR. PMID: 36052495.
      View in: PubMed   Mentions:    Fields:    
    8. Novel Regulators of Macropinocytosis-Dependent Growth Revealed by Informer Set Library Screening in Pancreatic Cancer Cells. Metabolites. 2022 Sep 02; 12(9). Kim SH, Song JH, Kim MJ, Song MG, Ku AA, Bandyopadhyay S, McCormick F, Kim SE. PMID: 36144235; PMCID: PMC9502772.
      View in: PubMed   Mentions:
    9. Abstract PO017: HBV alters YAP regulation in liver cancer by remodeling PP2A complexes. Clinical Cancer Research. 2022 Sep 1; 28(17_Supplement):po017-po017. Gordan GJ, Pitea PA, Turnham TR, Eckhardt EM, Jang JG, Lim LH, Choi CA, Bandyopadhyay BS, Swaney SD, Shokat SK, Ideker IT, Krogan KN. .
      View in: Publisher Site   Mentions:
    10. Trans-channel fluorescence learning improves high-content screening for Alzheimer's disease therapeutics. Nat Mach Intell. 2022 Jun; 4(6):583-595. Wong DR, Conrad J, Johnson N, Ayers J, Laeremans A, Lee JC, Lee J, Prusiner SB, Bandyopadhyay S, Butte AJ, Paras NA, Keiser MJ. PMID: 36276634; PMCID: PMC9585544.
      View in: PubMed   Mentions: 5  
    11. UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth. Proc Natl Acad Sci U S A. 2021 08 03; 118(31). Wolfe AL, Zhou Q, Toska E, Galeas J, Ku AA, Koche RP, Bandyopadhyay S, Scaltriti M, Lebrilla CB, McCormick F, Kim SE. PMID: 34330832; PMCID: PMC8346792.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    12. Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. Clin Cancer Res. 2021 Jul 15; 27(14):4129. Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Wechsler EI, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR. PMID: 34261774.
      View in: PubMed   Mentions:    Fields:    
    13. Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):9074-9074. Blakely BC, Gubens GM, Allen AG, Shah SS, Jereza JM, Bacaltos BB, Bandyopadhyay BS. .
      View in: Publisher Site   Mentions:
    14. Aurora kinases shed light on resistance to EGFR inhibition in head and neck cancer. EBioMedicine. 2021 03; 65:103257. Kim D, Bandyopadhyay S. PMID: 33639398; PMCID: PMC7918271.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK. Mol Cancer Ther. 2020 11; 19(11):2382-2395. Pucciarelli D, Angus SP, Huang B, Zhang C, Nakaoka HJ, Krishnamurthi G, Bandyopadhyay S, Clapp DW, Shannon K, Johnson GL, Nakamura JL. PMID: 32847978; PMCID: PMC7907257.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    16. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell. 2020 09 03; 182(5):1232-1251.e22. Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG. PMID: 32822576; PMCID: PMC7484178.
      View in: PubMed   Mentions: 253     Fields:    Translation:HumansCells
    17. Abstract 1470: UGP2 is a critical regulator of protein glycosylation in pancreatic cancer. Cancer Research. 2020 Aug 15; 80(16_Supplement):1470-1470. Wolfe WA, Galeas GJ, Toska TE, Zhou ZQ, Ku KA, Koche KR, Bandyopadhyay BS, Lebrilla LC, Scaltriti SM, McCormick MF, Kim KS. .
      View in: Publisher Site   Mentions:
    18. Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC. J Invest Dermatol. 2021 02; 141(2):364-373. Wu CH, Yang CY, Wang L, Gao HX, Rakhshandehroo T, Afghani S, Pincus L, Balassanian R, Rubenstein J, Gill R, Bandyopadhyay S, McCormick F, Moasser M, Ai WZ. PMID: 32603749; PMCID: PMC10286854.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    19. Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility. Nat Commun. 2020 05 12; 11(1):2375. Ku AA, Hu HM, Zhao X, Shah KN, Kongara S, Wu D, McCormick F, Balmain A, Bandyopadhyay S. PMID: 32398776; PMCID: PMC7217969.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    20. B01 Active YAP as a Functional Marker of Drug-Tolerant Persister Cells in EGFR-Mutant and ALK Fusion-Positive NSCLC. Journal of Thoracic Oncology. 2020 Feb 1; 15(2):s27. Haderk HF, Fernández-Méndez FC, Shah SK, Wu WW, Guan GJ, Rotow RJ, Allegakoen AD, Olivas OV, Bandyopadhyay BS, Kuo KC, Bivona BT. .
      View in: Publisher Site   Mentions:
    21. Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models. Blood. 2019 Nov 13; 134(Supplement_1):1578-1578. WU WC, Yang YC, Wang WL, Gao GH, Taha TR, Afghani AS, Pincus PL, Balassanian BR, Rubenstein RJ, Gill GR, Bandyopadhyay BS, McCormick MF, Moasser MM, Ai AW. .
      View in: Publisher Site   Mentions:
    22. Abstract 2902: Non-genetic TPX2/AURKA signaling facilitates tumor evolution in EGFR-TKI resistance in NSCLC. Tumor Biology. 2019 Jul 1; 2902-2902. Shah SK, Bhatt BR, Rotow RJ, Rohrberg RJ, Olivas OV, Wang WV, Kuhn KJ, Dumont DS, Mccormick MF, Goga GA, Blakely BC, Bivona BT, Bandyopadhyay BS. .
      View in: Publisher Site   Mentions:
    23. Targeting the evolution of drug resistance in lung cancer. Mol Cell Oncol. 2019; 6(5):e1603092. Shah KN, Bandyopadhyay S. PMID: 31528688; PMCID: PMC6736160.
      View in: PubMed   Mentions: 2  
    24. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat Med. 2019 01; 25(1):111-118. Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S. PMID: 30478424; PMCID: PMC6324945.
      View in: PubMed   Mentions: 128     Fields:    Translation:HumansAnimalsCells
    25. Integration of Tumor Genomic Data with Cell Lines Using Multi-dimensional Network Modules Improves Cancer Pharmacogenomics. Cell Syst. 2018 11 28; 7(5):526-536.e6. Webber JT, Kaushik S, Bandyopadhyay S. PMID: 30414925; PMCID: PMC6265063.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    26. P1.13-10 Aurora Kinase A Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer. Journal of Thoracic Oncology. 2018 Oct 1; 13(10):s585-s586. Shah SK, Blakely BC, Bivona BT, Bandyopadhyay BS. .
      View in: Publisher Site   Mentions:
    27. Abstract A45: Kinome rewiring reveals AURKA is a molecular barrier to the efficacy of PI3K/mTOR-pathway inhibitors in breast cancer. Resistance Mechanisms. 2018 Aug 1; a45-a45. Donnella DH, Webber WJ, Shokat SK, Goga GA, Gordan GJ, Bandyopadhyay BS. .
      View in: Publisher Site   Mentions:
    28. Abstract 3297: A tyrosine kinase interactome reveals network states that guide the use of targeted therapies in cancer. Bioinformatics and Systems Biology. 2018 Jul 1; 3297-3297. Kaushik KS, Jang JG, Hu HH, Shah SK, Zhao ZX, Jascur JJ, Dollen DJ, Verschueren VE, Johnson JJ, Krogan KN, Bandyopadhyay BS. .
      View in: Publisher Site   Mentions:
    29. Abstract 798: Pathway-directed high-throughput drug screen identifies PI3K inhibitors that synergistically potentiate antitumor activity of HDAC inhibitors in cutaneous T-cell lymphoma. Experimental and Molecular Therapeutics. 2018 Jul 1; 798-798. Wu WC, Yang YC, Rakhshandhroo RT, Pincus PL, Bandyopadhyay BS, McCormick MF, Ai AW. .
      View in: Publisher Site   Mentions:
    30. Abstract 1957: Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Experimental and Molecular Therapeutics. 2018 Jul 1; 1957-1957. Shah SK, Bhatt BR, Rotow RJ, Rohrberg RJ, Olivas OV, Hemmati HG, Krings KG, Haringsma HH, Simmons SA, Harding HT, Goga GA, Blakely BC, Bivona BT, Bandyopadhyay BS. .
      View in: Publisher Site   Mentions:
    31. Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. Nat Chem Biol. 2018 08; 14(8):768-777. Donnella HJ, Webber JT, Levin RS, Camarda R, Momcilovic O, Bayani N, Shah KN, Korkola JE, Shokat KM, Goga A, Gordan JD, Bandyopadhyay S. PMID: 29942081; PMCID: PMC6051919.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    32. A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance. Cell Rep. 2018 Apr 17; 23(3):918-929. Hu HM, Zhao X, Kaushik S, Robillard L, Barthelet A, Lin KK, Shah KN, Simmons AD, Raponi M, Harding TC, Bandyopadhyay S. PMID: 29669295; PMCID: PMC5935461.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    33. Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Res. 2018 05 01; 78(9):2383-2395. Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR. PMID: 29440171; PMCID: PMC6537867.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    34. Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. Elife. 2018 01 23; 7. Martinko AJ, Truillet C, Julien O, Diaz JE, Horlbeck MA, Whiteley G, Blonder J, Weissman JS, Bandyopadhyay S, Evans MJ, Wells JA. PMID: 29359686; PMCID: PMC5796798.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    35. Abstract PR04: HER3 crosstalk with HPV16-E6E7 is a feedback resistance mechanism to PI3K-targeted therapies in head and neck cancer. Viral Cancers HPV/EBV. 2017 Dec 1; pr04-pr04. Brand BT, Hartmann HS, Bhola BN, Li LH, Zeng ZY, O'Keefe OR, Ranall RM, Bandyopadhyay BS, Soucheray SM, Swaney SD, Krogan KN, Kemp KC, Duvvuri DU, Johnson JD, Ozbun OM, Bauman BJ, Grandis GJ. .
      View in: Publisher Site   Mentions:
    36. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. Clin Cancer Res. 2017 Jun 15; 23(12):3072-3083. Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR. PMID: 27986750; PMCID: PMC5474133.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    37. Connecting tumor genomics with therapeutics through multi-dimensional network modules. BioArxiv. 2016. Webber JT, Ranall MV, Kaushik S, Bandyopadhyay S. View Publication.
    38. Protein Sialylation Regulates a Gene Expression Signature that Promotes Breast Cancer Cell Pathogenicity. ACS Chem Biol. 2016 08 19; 11(8):2131-9. Kohnz RA, Roberts LS, DeTomaso D, Bideyan L, Yan P, Bandyopadhyay S, Goga A, Yosef N, Nomura DK. PMID: 27380425; PMCID: PMC4994060.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    39. Challenges in identifying cancer genes by analysis of exome sequencing data. Nat Commun. 2016 07 15; 7:12096. Hofree M, Carter H, Kreisberg JF, Bandyopadhyay S, Mischel PS, Friend S, Ideker T. PMID: 27417679; PMCID: PMC4947162.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    40. Abstract 388: Pathway-directed high throughput drug screen identifies PI3K inhibitors that synergistically potentiate anti-tumor activity of HDAC inhibitors in mycosis fungoides and Sézary syndrome. Experimental and Molecular Therapeutics. 2016 Jul 15; 388-388. Yang YC, Faraj FR, Rakhshandaroo RT, Afghani AS, Pincus PL, Bandyopadhyay BS, McCormick MF, Ai AW. .
      View in: Publisher Site   Mentions:
    41. Abstract 1205: HER3 is a functional molecular target in HPV-associated head and neck cancer. Experimental and Molecular Therapeutics. 2016 Jul 15; 1205-1205. Brand BT, Hartmann HS, Bhola BN, Peyser PN, Li LH, Zeng ZY, Randall RM, Bandyopadhyay BS, Grandis GJ. .
      View in: Publisher Site   Mentions:
    42. Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. Mol Cancer Ther. 2016 07; 15(7):1472-84. Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A. PMID: 27364904.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    43. Abstract C88: Genomics, advocacy, and emerging therapeutics to address triple-negative breast cancer (TNBC) outcome disparities. Community Groups and Advocacy. 2016 Mar 1; c88-c88. Samson SS, Zhou ZA, Martins MM, Corella CA, Horiuchi HD, Yau YC, Rakshandehroo RT, Gordan GJ, Levin LR, Johnson JJ, Jascur JJ, Shales SM, Sorrentino SA, Cheah CJ, Clemens CP, Shamji SA, Schreiber SS, Krogan KN, Shokat SK, McCormick MF, Bandyopadhyay BS, Goga GA. .
      View in: Publisher Site   Mentions:
    44. Pathway-Directed High Throughput Drug Screen Identifies PI3K Inhibitors That Synergistically Potentiate Anti-Tumor Activity of HDAC Inhibitors in Mycosis Fungoides and Sezary Syndrome. Blood. 2015 Dec 3; 126(23):2755-2755. Ai AW, Yang YC, Faraj FR, Rakhshandhroo RT, Afghani AS, Pincus PL, Bandyopadhyay BS, McCormick MF. .
      View in: Publisher Site   Mentions:
    45. Abstract B44: A systems approach combining genomics, advocacy, and emerging novel therapeutics to address triple-negative breast cancer (TNBC) outcomes disparities. Organ Site Research. 2015 Oct 1; b44-b44. Zhou ZA, Martins MM, Corella CA, Horiuchi HD, Yau YC, Rakshandehroo RT, Gordan GJ, Levin LR, Johnson JJ, Jascur JJ, Shales SM, Sorrentino SA, Cheah CJ, Clemons CP, Shamji SA, Schreiber SS, Krogan KN, Shokat SK, McCormick MF, Samson SS, Goga GA, Bandyopadhyay BS. .
      View in: Publisher Site   Mentions:
    46. Abstract B48: Identification of novel drug interactions with MYC via a quantitative chemical-genetic interaction map. Therapeutic Translation. 2015 Oct 1; b48-b48. Zhou ZA, Martins MM, Corella CA, Horiuchi HD, Yau YC, Rakshandehroo RT, Gordan GJ, Levin LR, Johnson JJ, Jascur JJ, Shales SM, Sorrentino SA, Cheah CJ, Clemons CP, Shamji SA, Schreiber SS, Krogan KN, Shokat SK, McCormick MF, Goga GA, Bandyopadhyay BS. .
      View in: Publisher Site   Mentions:
    47. Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions. Cancer Res. 2015 Jul 15; 75(14):2851-62. Fujita-Sato S, Galeas J, Truitt M, Pitt C, Urisman A, Bandyopadhyay S, Ruggero D, McCormick F. PMID: 25977330; PMCID: PMC4506276.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    48. Activity-Based Protein Profiling of Oncogene-Driven Changes in Metabolism Reveals Broad Dysregulation of PAFAH1B2 and 1B3 in Cancer. ACS Chem Biol. 2015 Jul 17; 10(7):1624-30. Kohnz RA, Mulvihill MM, Chang JW, Hsu KL, Sorrentino A, Cravatt BF, Bandyopadhyay S, Goga A, Nomura DK. PMID: 25945974; PMCID: PMC4702252.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    49. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 2015 Apr 07; 11(1):98-110. Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG. PMID: 25843712; PMCID: PMC4394036.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansCells
    50. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer Discov. 2015 02; 5(2):154-67. Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakhshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, Schreiber SL, Krogan NJ, Shokat KM, McCormick F, Goga A, Bandyopadhyay S. PMID: 25501949; PMCID: PMC4407699.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    51. 73 Differential pathway resiliency in response to MAPK inhibition in BRAF-mutant cancer. European Journal of Cancer. 2014 Nov 1; 50:28-29. Sos SM, Levin LR, Gordan GJ, Oses-Prieto OJ, Webber WJ, Salt SM, Hann HB, Burlingame BA, McCormick MF, Bandyopadhyay BS, Shokat SK. .
      View in: Publisher Site   Mentions:
    52. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep. 2014 Aug 21; 8(4):1037-48. Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM. PMID: 25127139; PMCID: PMC4294625.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    53. Inositol phosphate recycling regulates glycolytic and lipid metabolism that drives cancer aggressiveness. ACS Chem Biol. 2014 Jun 20; 9(6):1340-50. Benjamin DI, Louie SM, Mulvihill MM, Kohnz RA, Li DS, Chan LG, Sorrentino A, Bandyopadhyay S, Cozzo A, Ohiri A, Goga A, Ng SW, Nomura DK. PMID: 24738946; PMCID: PMC4076040.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    54. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A. 2014 Feb 18; 111(7):E748-57. Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, Solit DB, Collisson EA, Rudin CM, Taylor BS, Bivona TG. PMID: 24550319; PMCID: PMC3932924.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    55. Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov. 2014 Feb; 4(2):186-99. Salt MB, Bandyopadhyay S, McCormick F. PMID: 24302555.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCells
    56. Operational Signaling Pathways in Radiation-Induced Tumors. International Journal of Radiation Oncology • Biology • Physics. 2013 Oct 1; 87(2):s627. Braunstein BS, Mroue MR, Huang HB, Bandyopadhyay BS, Nakamura NJ. .
      View in: Publisher Site   Mentions:
    57. Bringing it all together: big data and HIV research. AIDS. 2013 Mar 13; 27(5):835-8. Bushman FD, Barton S, Bailey A, Greig C, Malani N, Bandyopadhyay S, Young J, Chanda S, Krogan N. PMID: 23719353; PMCID: PMC3671485.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    58. Quantitative genetic-interaction mapping in mammalian cells. Nat Methods. 2013 May; 10(5):432-7. Roguev A, Talbot D, Negri GL, Shales M, Cagney G, Bandyopadhyay S, Panning B, Krogan NJ. PMID: 23407553; PMCID: PMC3641890.
      View in: PubMed   Mentions: 63     Fields:    Translation:AnimalsCells
    59. Rewiring of genetic networks in response to DNA damage. Science. 2010 Dec 03; 330(6009):1385-9. Bandyopadhyay S, Mehta M, Kuo D, Sung MK, Chuang R, Jaehnig EJ, Bodenmiller B, Licon K, Copeland W, Shales M, Fiedler D, Dutkowski J, Guénolé A, van Attikum H, Shokat KM, Kolodner RD, Huh WK, Aebersold R, Keogh MC, Krogan NJ, Ideker T. PMID: 21127252; PMCID: PMC3006187.
      View in: PubMed   Mentions: 230     Fields:    Translation:AnimalsCells
    60. Coevolution within a transcriptional network by compensatory trans and cis mutations. Genome Res. 2010 Dec; 20(12):1672-8. Kuo D, Licon K, Bandyopadhyay S, Chuang R, Luo C, Catalana J, Ravasi T, Tan K, Ideker T. PMID: 20978140; PMCID: PMC2989993.
      View in: PubMed   Mentions: 41     Fields:    Translation:AnimalsCells
    61. A human MAP kinase interactome. Nat Methods. 2010 Oct; 7(10):801-5. Bandyopadhyay S, Chiang CY, Srivastava J, Gersten M, White S, Bell R, Kurschner C, Martin C, Smoot M, Sahasrabudhe S, Barber DL, Chanda SK, Ideker T. PMID: 20936779; PMCID: PMC2967489.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansAnimalsCells
    62. Human host factors required for influenza virus replication. Nature. 2010 Feb 11; 463(7282):813-7. König R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Ortigoza MB, Liang Y, Gao Q, Andrews SE, Bandyopadhyay S, De Jesus P, Tu BP, Pache L, Shih C, Orth A, Bonamy G, Miraglia L, Ideker T, García-Sastre A, Young JA, Palese P, Shaw ML, Chanda SK. PMID: 20027183; PMCID: PMC2862546.
      View in: PubMed   Mentions: 480     Fields:    Translation:HumansAnimalsCells
    63. Evolutionarily conserved herpesviral protein interaction networks. PLoS Pathog. 2009 Sep; 5(9):e1000570. Fossum E, Friedel CC, Rajagopala SV, Titz B, Baiker A, Schmidt T, Kraus T, Stellberger T, Rutenberg C, Suthram S, Bandyopadhyay S, Rose D, von Brunn A, Uhlmann M, Zeretzke C, Dong YA, Boulet H, Koegl M, Bailer SM, Koszinowski U, Ideker T, Uetz P, Zimmer R, Haas J. PMID: 19730696; PMCID: PMC2731838.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansCells
    64. Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog. 2009 May; 5(5):e1000437. Bushman FD, Malani N, Fernandes J, D'Orso I, Cagney G, Diamond TL, Zhou H, Hazuda DJ, Espeseth AS, König R, Bandyopadhyay S, Ideker T, Goff SP, Krogan NJ, Frankel AD, Young JA, Chanda SK. PMID: 19478882; PMCID: PMC2682202.
      View in: PubMed   Mentions: 267     Fields:    Translation:HumansCells
    65. A genetic interaction map of RNA-processing factors reveals links between Sem1/Dss1-containing complexes and mRNA export and splicing. Mol Cell. 2008 Dec 05; 32(5):735-46. Wilmes GM, Bergkessel M, Bandyopadhyay S, Shales M, Braberg H, Cagney G, Collins SR, Whitworth GB, Kress TL, Weissman JS, Ideker T, Guthrie C, Krogan NJ. PMID: 19061648; PMCID: PMC2644724.
      View in: PubMed   Mentions: 161     Fields:    Translation:AnimalsCells
    66. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell. 2008 Oct 03; 135(1):49-60. König R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, Irelan JT, Chiang CY, Tu BP, De Jesus PD, Lilley CE, Seidel S, Opaluch AM, Caldwell JS, Weitzman MD, Kuhen KL, Bandyopadhyay S, Ideker T, Orth AP, Miraglia LJ, Bushman FD, Young JA, Chanda SK. PMID: 18854154; PMCID: PMC2628946.
      View in: PubMed   Mentions: 598     Fields:    Translation:HumansCells
    67. Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast. Science. 2008 Oct 17; 322(5900):405-10. Roguev A, Bandyopadhyay S, Zofall M, Zhang K, Fischer T, Collins SR, Qu H, Shales M, Park HO, Hayles J, Hoe KL, Kim DU, Ideker T, Grewal SI, Weissman JS, Krogan NJ. PMID: 18818364; PMCID: PMC2753251.
      View in: PubMed   Mentions: 210     Fields:    Translation:AnimalsCells
    68. Functional maps of protein complexes from quantitative genetic interaction data. PLoS Comput Biol. 2008 Apr 18; 4(4):e1000065. Bandyopadhyay S, Kelley R, Krogan NJ, Ideker T. PMID: 18421374; PMCID: PMC2289880.
      View in: PubMed   Mentions: 79     Fields:    Translation:Cells
    69. Integrating physical and genetic maps: from genomes to interaction networks. Nat Rev Genet. 2007 Sep; 8(9):699-710. Beyer A, Bandyopadhyay S, Ideker T. PMID: 17703239; PMCID: PMC2811081.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCells
    70. Systematic identification of functional orthologs based on protein network comparison. Genome Res. 2006 Mar; 16(3):428-35. Bandyopadhyay S, Sharan R, Ideker T. PMID: 16510899; PMCID: PMC1415213.
      View in: PubMed   Mentions: 69     Fields:    Translation:Animals
    71. Discovering regulated networks during HIV-1 latency and reactivation. Pac Symp Biocomput. 2006; 354-66. Bandyopadhyay S, Kelley R, Ideker T. PMID: 17094252; PMCID: PMC5224933.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    72. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A. 2004 Jun 15; 101(24):9103-8. Canet-Avilés RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Petsko GA, Cookson MR. PMID: 15181200; PMCID: PMC428480.
      View in: PubMed   Mentions: 455     Fields:    Translation:HumansCells
    73. Evolutionary and functional relationships within the DJ1 superfamily. BMC Evol Biol. 2004 Feb 19; 4:6. Bandyopadhyay S, Cookson MR. PMID: 15070401; PMCID: PMC385224.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansAnimalsCells
    Sourav's Networks
    Concepts (292)
    Derived automatically from this person's publications.
    _
    Co-Authors (71)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _